Previous 10 | Next 10 |
CG-806 Phase 1 a/b Study in B Cell Malignancies Advances to Fifth (750mg) Dose Cohort FDA Allows IND for Phase 1 a/b Study of CG-806 in AML to Initiate at 450mg Dose Level APTO-253 Phase 1b Study in AML / MDS Advances to Fifth (150mg/m 2 ) Dose Cohort Conference Call and Webc...
SAN DIEGO and TORONTO, July 21, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended June 30...
Tricida (NASDAQ: TCDA ) -33% after FDA flags deficiencies in Veverimer. More news on: Tricida, Inc., INmune Bio, Inc., WISeKey International Holding AG, Stocks on the move, , Read more ...
Aptose Biosciences (NASDAQ: APTO ) has priced its public offering of 10.5M common shares at $5.25/share, for expected gross proceeds of ~$55M. More news on: Aptose Biosciences Inc., Healthcare stocks news, , Read more ...
Aptose (NASDAQ: APTO ) commences a public offering of its common shares. More news on: Aptose Biosciences Inc., Healthcare stocks news, Read more ...
Aptose Biosciences (NASDAQ: APTO ) is up 7% premarket in reaction to its announcement that the FDA has signed off on its IND application to initiate a Phase 1a/b clinical study of CG-806, an oral FLT3/BTK inhibitor, in patients with acute myeloid leukemia (AML). More news on:...
Oral FLT3/BTK inhibitor CG-806 expands development beyond B-cell malignancies to the treatment of AML Phase 1a/b study in B-cell malignancies continues through dose escalation SAN DIEGO and TORONTO, June 29, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS),...
Biotech has outpaced nearly every other sector this year in growth. While the S&P 500 was down 3.6% for the year as of Wednesday, the NASDAQ Biotechnology Index (NBI) is up 10.5% in 2020. That growth carries an enormous amount of risk, however, as many biotech companies aren't mak...
New clinical data on Aptose Biosciences' (NASDAQ: APTO ) CG-806, an oral, FLT3/BTK cluster selective kinase inhibitor, was presented at the 25 th Congress of the European Hematology Association. More news on: Aptose Biosciences Inc., Healthcare stocks news, Stocks on the move, Read ...
Safety, tolerability and phospho-BTK inhibition at first three CG-806 dose levels in patients with CLL and other B-cell malignancies Plasma from CG-806 treated patients completely inhibited phospho-FLT3, suggesting current dose levels may be therapeutic in patients with AML New IN...
News, Short Squeeze, Breakout and More Instantly...
Aptose Biosciences Inc. Company Name:
APTO Stock Symbol:
NASDAQ Market:
Aptose Biosciences Inc. Website:
SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, t...
SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies,...
TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AML TUS Monotherapy and TUS+VEN Doublet Therapy Active in...